Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Galecto Inc
(NQ:
GLTO
)
0.5401
-0.0124 (-2.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Galecto Inc
Galecto Inc. (NASDAQ: GLTO) Leading the Way in Tuesday Trading Based on Percentage Gain
July 25, 2023
Via
Investor Brand Network
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
March 09, 2023
From
Galecto, Inc.
Via
GlobeNewswire
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 02, 2023
From
Galecto, Inc.
Via
GlobeNewswire
Galecto to Participate in SVB Securities Global Biopharma Conference
February 01, 2023
From
Galecto, Inc.
Via
GlobeNewswire
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
December 07, 2022
From
Galecto, Inc.
Via
GlobeNewswire
Galecto Reports Third Quarter Operating and Financial Results
November 08, 2022
From
Galecto, Inc.
Via
GlobeNewswire
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
November 08, 2022
From
Galecto, Inc.
Via
GlobeNewswire
Galecto to Participate in Jefferies London Healthcare Conference
November 03, 2022
From
Galecto, Inc.
Via
GlobeNewswire
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
October 31, 2022
From
Galecto, Inc.
Via
GlobeNewswire
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
October 19, 2022
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor
From
Galecto, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.